PortfoliosLab logoPortfoliosLab logo
VKTX vs. SNDX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

VKTX vs. SNDX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Viking Therapeutics, Inc. (VKTX) and Syndax Pharmaceuticals, Inc. (SNDX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, VKTX achieves a -16.74% return, which is significantly lower than SNDX's -12.47% return. Over the past 10 years, VKTX has outperformed SNDX with an annualized return of 35.06%, while SNDX has yielded a comparatively lower 3.37% annualized return.


VKTX

1D
-6.33%
1M
-2.37%
YTD
-16.74%
6M
-13.55%
1Y
12.14%
3Y*
9.55%
5Y*
40.92%
10Y*
35.06%

SNDX

1D
-2.44%
1M
-3.77%
YTD
-12.47%
6M
-2.13%
1Y
67.49%
3Y*
-3.51%
5Y*
0.53%
10Y*
3.37%
*Multi-year figures are annualized to reflect compound growth (CAGR)

VKTX vs. SNDX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
VKTX
Viking Therapeutics, Inc.
-16.74%-12.57%116.23%97.98%104.35%-18.29%-29.80%4.84%88.42%241.18%
SNDX
Syndax Pharmaceuticals, Inc.
-12.47%58.93%-38.82%-15.09%16.26%-1.57%153.30%97.30%-49.20%22.18%

Correlation

The correlation between VKTX and SNDX is 0.38, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.38

Correlation (3Y)
Calculated over the trailing 3-year period

0.36

Correlation (5Y)
Calculated over the trailing 5-year period

0.37

Correlation (10Y)
Calculated over the trailing 10-year period

0.29

Correlation (All Time)
Calculated using the full available price history since Mar 4, 2016

0.27

The correlation between VKTX and SNDX shifts across timeframes, from 0.27 (all time) to 0.38 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

EPS

VKTX:

-$4.16

SNDX:

-$3.75

Total Revenue (TTM)

VKTX:

$0.00

SNDX:

$217.17M

Gross Profit (TTM)

VKTX:

-$208.00K

SNDX:

$208.46M

EBITDA (TTM)

VKTX:

-$501.77M

SNDX:

-$171.20M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

VKTX vs. SNDX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

VKTX
VKTX Risk / Return Rank: 4747
Overall Rank
VKTX Sharpe Ratio Rank: 4646
Sharpe Ratio Rank
VKTX Sortino Ratio Rank: 4848
Sortino Ratio Rank
VKTX Omega Ratio Rank: 5151
Omega Ratio Rank
VKTX Calmar Ratio Rank: 4545
Calmar Ratio Rank
VKTX Martin Ratio Rank: 4545
Martin Ratio Rank

SNDX
SNDX Risk / Return Rank: 7676
Overall Rank
SNDX Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
SNDX Sortino Ratio Rank: 7676
Sortino Ratio Rank
SNDX Omega Ratio Rank: 7070
Omega Ratio Rank
SNDX Calmar Ratio Rank: 8080
Calmar Ratio Rank
SNDX Martin Ratio Rank: 8080
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

VKTX vs. SNDX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Viking Therapeutics, Inc. (VKTX) and Syndax Pharmaceuticals, Inc. (SNDX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


VKTXSNDXDifference

Sharpe ratio

Return per unit of total volatility

0.17

1.19

-1.02

Sortino ratio

Return per unit of downside risk

0.75

2.08

-1.33

Omega ratio

Gain probability vs. loss probability

1.12

1.23

-0.11

Calmar ratio

Return relative to maximum drawdown

0.21

2.77

-2.57

Martin ratio

Return relative to average drawdown

0.42

6.75

-6.33

VKTX vs. SNDX - Sharpe Ratio Comparison

The current VKTX Sharpe Ratio is 0.17, which is lower than the SNDX Sharpe Ratio of 1.19. The chart below compares the historical Sharpe Ratios of VKTX and SNDX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


VKTXSNDXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.17

1.19

-1.02

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.41

0.01

+0.40

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.36

0.05

+0.32

Sharpe Ratio (All Time)

Calculated using the full available price history

0.11

0.06

+0.05

Drawdowns

VKTX vs. SNDX - Drawdown Comparison

The maximum VKTX drawdown since its inception was -90.41%, which is greater than SNDX's maximum drawdown of -78.98%. Use the drawdown chart below to compare losses from any high point for VKTX and SNDX.


Loading charts...

Drawdown Indicators


VKTXSNDXDifference

Max Drawdown

Largest peak-to-trough decline

-90.41%

-78.98%

-11.43%

Max Drawdown (1Y)

Largest decline over 1 year

-45.14%

-26.88%

-18.26%

Max Drawdown (3Y)

Largest decline over 3 years

-78.86%

-64.81%

-14.05%

Max Drawdown (5Y)

Largest decline over 5 years

-78.86%

-69.88%

-8.98%

Max Drawdown (10Y)

Largest decline over 10 years

-89.26%

-78.98%

-10.28%

Current Drawdown

Current decline from peak

-69.01%

-36.54%

-32.47%

Average Drawdown

Average peak-to-trough decline

-60.00%

-35.81%

-24.19%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.21%

11.03%

+11.18%

Volatility

VKTX vs. SNDX - Volatility Comparison

Viking Therapeutics, Inc. (VKTX) has a higher volatility of 14.94% compared to Syndax Pharmaceuticals, Inc. (SNDX) at 12.12%. This indicates that VKTX's price experiences larger fluctuations and is considered to be riskier than SNDX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


VKTXSNDXDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.94%

12.12%

+2.82%

Volatility (6M)

Calculated over the trailing 6-month period

41.78%

32.76%

+9.02%

Volatility (1Y)

Calculated over the trailing 1-year period

73.90%

57.31%

+16.59%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

101.62%

54.80%

+46.82%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

97.11%

71.18%

+25.93%

Dividends

VKTX vs. SNDX - Dividend Comparison

Neither VKTX nor SNDX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

VKTX vs. SNDX - Financials Comparison

This section allows you to compare key financial metrics between Viking Therapeutics, Inc. and Syndax Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M120.00M202220232024202520260
64.86M
(VKTX) Total Revenue
(SNDX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


VKTX and SNDX have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

VKTX has higher volatility (14.94%) compared to SNDX (12.12%). In terms of maximum drawdown, VKTX dropped -90.41% vs SNDX's -78.98%.

SNDX currently has the higher Sharpe Ratio (1.19 vs 0.17), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for VKTX and SNDX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer